ERBB3 and neoplasm: In an early analysis of the data, low ErbB3/HER3 mRNA levels as measured in 122 of the 130 patient archival tumor tissues appeared to predict clinical benefit in the cohort receiving gemcitabine + pertuzumab versus the gemcitabine + placebo group [54].